Recently, it has been shown that some of the tyrosine kinase inhibitors (TKIs) could be used as MDR reversal agents in combination with conventional anticancer drugs [21], which could inhibit the efflux of anticancer drugs in drug-resistant cancer cells with overexpression of ABC transporters [9,10]. The gene discussed is ABCG2; the disease is cancer.